Loading…
BiomX Inc. is projected to rise to $1.84 by 2027, a +19% move from its current price of $1.55. PHGE is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.37 | $1.55 | $1.75 | +0.02% |
| May 30 | $1.31 | $1.55 | $1.84 | +0.04% |
| May 31 | $1.26 | $1.55 | $1.91 | +0.05% |
| Jun 1 | $1.22 | $1.55 | $1.97 | +0.07% |
| Jun 2 | $1.19 | $1.55 | $2.03 | +0.09% |
| Jun 3 | $1.16 | $1.55 | $2.08 | +0.11% |
| Jun 4 | $1.13 | $1.55 | $2.13 | +0.12% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.13 | $1.55 | $2.13 | +0.12% |
| Week 2 | $0.9912 | $1.55 | $2.44 | +0.25% |
| Week 3 | $0.8971 | $1.56 | $2.70 | +0.37% |
| Week 4 | $0.8249 | $1.56 | $2.94 | +0.50% |
| Week 5 | $0.7662 | $1.56 | $3.17 | +0.62% |
| Week 6 | $0.7168 | $1.56 | $3.40 | +0.74% |
| Week 7 | $0.6743 | $1.56 | $3.63 | +0.87% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BiomX Inc. is a clinical-stage biopharmaceutical company that develops phage-based therapies designed to target and kill specific harmful bacteria associated with chronic diseases. Its phage-based therapies include fixed cocktail therapy, which involves developing a single product containing a fixed number of selected phages to cover a range of bacterial strains; and personalized therapy, which involves developing a large library of phages from which single optimal phages are personally matched to treat specific patients.
BiomX is currently advancing BX011, a fixed multi-phage cocktail, in Phase 2a trial for the treatment of diabetic foot infections, and BX211, a phage therapy, in Phase 2 trial for the treatment of diabetic foot osteomyelitis. BiomX Inc. was founded in 2015 and is based in Dover, Delaware.
As a healthcare company focused on phage-based approaches, BiomX operates in the category of healthcare and is engaged in clinical development of therapies targeting bacterial infections linked to chronic conditions.
BiomX Inc. (PHGE) trades with a current price of $1.55 and a market cap of $15.73M, ranking 4966 by market listing. The near-term technicals show a neutral stance with a 30-day price range of $0.7021 to $3.42, reflecting notable volatility around a sub-$2 to low-$3 price band.
The multi-year forecast outlines a gradual upward trajectory beyond 2026, with the 2026 avg price at $1.55 and subsequent years showing rising averages into the 2030s and beyond. Notably, 2032-2034 are labeled bullish, and the 2040 and 2050 forecasts project higher averages, culminating in an average of $5.65 by 2050 with a max forecast of $13.00. The long-run upside is quantified by a 264.6% ROI in 2050 and a bullish outlook for later years, tempered by earlier-year negatives such as a -9.2% ROI in 2030.
In the near term, BiomX exhibits a neutral sentiment with data points including RSI of 60, a 50-day simple moving average of $2.16, a 200-day simple moving average of $5.66, and defined support at $0.374 and resistance at $1.97. This places the current price in a context of potential upside, but with substantial variability implied by the 30-day range.
A major floor 75.9% below — a decisive break under it would weaken the trend.
The nearest floor, 75.9% below — buyers have tended to step in here.
The nearest ceiling, 27.1% above — a clean break opens room to run.
A major ceiling 383.9% above — clearing it would confirm fresh momentum.
Key PHGE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PHGE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.06 | Buy | $1.17 | Buy |
| MA 10 | $0.7899 | Buy | $0.963 | Buy |
| MA 20 | $0.7404 | Buy | $1.02 | Buy |
| MA 50 | $2.16 | Sell | $1.96 | Sell |
| MA 100 | $3.44 | Sell | $3.20 | Sell |
| MA 200 | $5.66 | Sell | $5.66 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.99 | Neutral |
| Stoch RSI (14) | 95.37 | Sell |
| CCI (20) | 279.02 | Buy |
| Williams %R (14) | -5.62 | Info |
| MACD (12,26,9) | 0.22 | Buy |
| ROC (12) | 147.21 | Buy |
| Bollinger %B (20,2) | 1.17 | Sell |
| Stochastic %K (14) | 94.38 | Sell |
| TRIX (15) | -4.41 | Sell |
| Awesome (5,34) | -0.11 | Sell |
| Ultimate (7,14,28) | 76.52 | Sell |
| Momentum (10) | 0.91 | Buy |
| Aroon Osc (25) | 16.00 | Buy |
| Hull MA (9) | 1.44 | Buy |
| ADX (14) | 42.77 | Buy |
| ATR (14) | 0.16 | Info |
Near term, the technical picture is NEUTRAL. RSI(14) sits at 60, indicating neither overbought nor oversold conditions. The 50-day moving average sits at $2.16, while the 200-day moving average stands at $5.66. A defined support level is at $0.374 and a resistance level at $1.97.
Over the last 30 days, the price has moved within a range of $0.7021 to $3.42, underscoring the volatility surrounding the current price of $1.55 and its proximity to the near-term resistance. These factors frame a cautious stance in the immediate horizon, with potential for movement toward the resistance around $1.97 if momentum builds.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.374 | $1.55 | $2.59 | 0% | Neutral | |
| $1.32 | $1.84 | $2.76 | +19% | Neutral | |
| $1.07 | $1.58 | $2.53 | +2% | Neutral | |
| $0.9593 | $1.49 | $2.50 | -4% | Neutral | |
| $0.865 | $1.41 | $2.45 | -9% | Neutral | |
| $1.03 | $1.74 | $3.15 | +13% | Neutral | |
| $1.17 | $2.08 | $3.86 | +34% | Bullish | |
| $1.15 | $2.13 | $4.06 | +37% | Bullish | |
| $1.10 | $2.11 | $4.13 | +36% | Bullish | |
| $0.9056 | $1.81 | $3.62 | +17% | Neutral | |
| $1.11 | $2.46 | $5.41 | +59% | Bullish | |
| $2.54 | $5.65 | $13.00 | +265% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.374 | $1.55 | $1.86 | +0.00% |
| June 2026 | $1.37 | $1.64 | $2.04 | +5.73% |
| July 2026 | $1.29 | $1.58 | $2.01 | -3.88% |
| August 2026 | $1.29 | $1.59 | $2.07 | +1.21% |
| September 2026 | $1.39 | $1.74 | $2.29 | +9.06% |
| October 2026 | $1.42 | $1.79 | $2.40 | +3.02% |
| November 2026 | $1.39 | $1.78 | $2.41 | -0.79% |
| December 2026 | $1.47 | $1.89 | $2.59 | +6.34% |
Click any year to see its month-by-month PHGE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, PHGE is projected to trade between $0.374 and $2.59, averaging $1.55 — a potential gain of 0% from today's $1.55. A consolidation phase looks the most probable path here.
BiomX Inc.'s 2027 outlook centres on $1.84, within a $1.32 to $2.76 range. That is up +19% on the projected 2026 average. That marks a +19% change versus current levels. Price action looks broadly range-bound.
By 2028, PHGE could reach as high as $2.53, with a base case around $1.58 and support toward $1.07 — roughly +2% from $1.55. A consolidation phase looks the most probable path here.
Expect PHGE to range from $0.9593 to $2.50 through 2029. The $1.49 average target implies a -4% move from current prices. That is -6% versus the projected 2028 average. Price action looks broadly range-bound.
The PHGE price prediction for 2030 points to an average of $1.41 (low $0.865, high $2.45) — a potential decline of -9% on today's $1.55. A consolidation phase looks the most probable path here.
In 2031, PHGE is projected to trade between $1.03 and $3.15, averaging $1.74 — a potential gain of +13% from today's $1.55. That is up +24% on the projected 2030 average. Price action looks broadly range-bound.
BiomX Inc.'s 2032 outlook centres on $2.08, within a $1.17 to $3.86 range. That is up +19% on the projected 2031 average. That marks a +34% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, PHGE could reach as high as $4.06, with a base case around $2.13 and support toward $1.15 — roughly +37% from $1.55. Momentum favours further upside here.
Expect PHGE to range from $1.10 to $4.13 through 2034. The $2.11 average target implies a +36% move from current prices. That is -1% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The PHGE price prediction for 2035 points to an average of $1.81 (low $0.9056, high $3.62) — a potential gain of +17% on today's $1.55. Price action looks broadly range-bound.
In 2040, PHGE is projected to trade between $1.11 and $5.41, averaging $2.46 — a potential gain of +59% from today's $1.55. That is up +36% on the projected 2035 average. Buyers look set to stay in control over this stretch.
BiomX Inc.'s 2050 outlook centres on $5.65, within a $2.54 to $13.00 range. That is up +130% on the projected 2040 average. That marks a +265% change versus current levels. Momentum favours further upside here.
Investing $1,000 in PHGE today (≈ 645.16129 PHGE) could be worth
$3,645.78
+$2,645.78 (+265%) by 2050 · US Dollar
Based on the average projected PHGE price of $5.65 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PHGEwould be worth at today's price.
$1,000 invested in PHGE on May 27, 2025 (≈ 101.801894 PHGE) would be worth
$157.79
-$842.21 (-84.2%) today · 0.16× · US Dollar
Based on a PHGE entry price of $9.82 vs. today's $1.55.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.597 | $2,596.31 | +159.6% |
| 1 month ago | $1.02 | $1,519.61 | +52.0% |
| 3 months ago | $4.57 | $339.17 | -66.1% |
| 6 months ago | $4.36 | $355.5 | -64.4% |
| 1 year ago | $9.82 | $157.79 | -84.2% |
| All time (5.0y) ago | $1,198.9 | $1.29 | -99.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PHGE forecast.
Our base-case forecast reaches $3.10 around 2050.
Implied market cap at $3.10: $31.45M
The multi-year forecast shows a path that is mixed through the mid-term and increasingly bullish later in the horizon. The 2030 forecast carries an average price of $1.41, with a minimum of $0.865 and a maximum of $2.45, and a RO I of -9.2%, reflecting a cautious stance at that point in time.
From 2032 onward, the outlook turns more positive, with 2032’s average at $2.08 and a bullish sentiment, followed by 2033 at $2.13 and 2034 at $2.11, both with bullish labels and ROI of 34% and 37.2% respectively. The 2040 forecast shows an average of $2.46 with a 58.8% ROI and bullish sentiment, highlighting stronger upside later in the decade.
By 2050, the forecast envisions a substantial rise to an average of $5.65 and a max of $13.00, with a 264.6% ROI and bullish sentiment. This indicates a meaningful long-run upside potential, contingent on continued development progress of its phage therapies (BX011 and BX211) and the broader clinical outcomes that support the platform. As with all forecasts, these figures are estimates and not guarantees, and they acknowledge substantial uncertainty and risk along the way.
Tap a question to reveal the answer.
2030 avg $1.41, min $0.865, max $2.45, ROI -9.2%, sentiment NEUTRAL.
Forecasts show a neutral stance in 2026 with later years turning bullish (2032-2034) and strong potential by 2050 (avg $5.65, max $13.00; ROI up to 264.6%). However, 2030 implies a negative ROI (-9.2%), and the outlook includes volatility and uncertainty.
Yes. The 2050 forecast lists an average of $5.65 and a maximum of $13.00, with a 264.6% ROI.
Current price is $1.55 and market cap is $15.73M.
The 30-day range is $0.7021 to $3.42.
BiomX Inc. Community Discussion
0Share your BiomX Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.